Stock data
Galectin Therapeutics Inc. (GALT)
Galectin Therapeutics Inc. (GALT) reported net income of -US$30.84M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$20.09M | -US$30.84M | — |
| 2024 | — | — | -US$42.43M | -US$47.05M | — |
| 2023 | — | — | -US$38.07M | -US$41.07M | — |
| 2022 | — | — | -US$38.35M | -US$38.78M | — |
| 2021 | — | — | -US$30.18M | -US$30.53M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$9.11M | — |
| 2026-03-31 | — | -US$5.05M | — |
| 2025-12-31 | — | -US$5.50M | — |
| 2025-09-30 | — | -US$8.18M | — |
| 2025-06-30 | — | -US$7.52M | — |
| 2025-03-31 | — | -US$9.63M | — |
| 2024-12-31 | — | -US$11.97M | — |
| 2024-09-30 | — | -US$11.22M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.